1. 3016Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension. (28th August 2018) Authors: Galie, N; Gaine, S; Channick, R; Ghofrani, H A; Hoeper, M; Lang, I; McLaughlin, V; Preiss, R; Rubin, L; Shiraga, Y; Simonneau, G; Sitbon, O; Tapson, V; Chin, K Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S122 Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension. (December 2018) Authors: Coghlan, JG; Galiè, N; Gaine, S; Channick, R; Ghofrani, H-A; Hoeper, M; Lang, I; McLaughlin, V; Preiss, R; Rubin, L; Shiraga, Y; Simonneau, G; Sitbon, O; Tapson, V; Chin, K Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis. (14th October 2021) Authors: Coghlan, G J; Gaine, S; Channick, R N; Chin, K M; Du Roure, C; Gibbs, J S R; Hoeper, M M; Lang, I M; Mathai, S C; McLaughlin, V V; Mitchell, L; Simonneau, G; Sitbon, O; Tapson, V; Galie, N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗